Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: HorvátországFázis nélkül

Evaluation of the DuoVT PFA System for Ventricular Tachycardia

A legfontosabb adatok

Ki végzi
Abbott Medical Devices
Hol
Split (Horvátország)A helyszín megnézéseMég 3 másik országban, 4 helyszínen
Azonosító
Állapot
Toboroz
Résztvevők
50 fő, tervezett
Kezdés
2026. szept. 29.
Várható befejezés
2027. júl. 30.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Ablation procedure with DuoVT PFA system
A regiszteradat frissítve
2026. október 16.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with sustained monomorphic ventricular tachycardia (a steady, fast heart rhythm from the lower heart chambers) after a heart attack, or with frequent extra heartbeats (PVCs). They will have an ablation with the DuoVT PFA system.

Életkor
18 to 80 years
Nem
All sexes
A betegség stádiuma
Group 1: sustained monomorphic VT with ischemic cardiomyopathy, a past heart attack, and at least one VT episode in the 180 days before joining. Group 2: frequent PVCs with a 24-hour monitor record in the 90 days before joining, and symptoms or a high PVC burden (>10% or >15%).
Korábbi kezelés
VT group: VT came back despite class I or III antiarrhythmic drugs, or these drugs are not tolerated, not allowed or not wanted. An ICD or CRT-D must already be implanted; transvenous leads at least 30 days before. PVC group with symptoms: class I or III drugs failed, were not tolerated or not wanted. Cannot join after any VT or PVC ablation in the past 90 days, or more than 1 in the past 365 days.

A részvétel fő kizáró okai

  • Heart attack, unstable angina or coronary stent procedure in the past 60 days, or heart surgery in the past 90 days
  • LVEF < 15%, NYHA Class IV or decompensated heart failure, or a heart pump (VAD) or ECMO
  • Stroke or mini-stroke in the past 90 days, or a blood clot inside the heart
  • eGFR < 30 mL/min/1.73 m², body mass index > 40 kg/m², or life expectancy under 12 months
  • Pregnancy or breastfeeding

A regiszter feltételei, szó szerint

Mind a 40 feltétel megnézéseKevesebb

Ki vehet részt

  • Sustained Monomorphic Ventricular Tachycardia (SMMVT) with Ischemic Cardiomyopathy (ICM); Patients with SMMVT and ischemic cardiomyopathy meet all of the following criteria:; History of myocardial infarction (MI); At least one episode of sustained (continuous for >30 seconds or requiring ICD intervention for termination) monomorphic ventricular tachycardia within the 180 days prior to enrollment; SMMVT recurrence despite class I or III antiarrhythmic drug therapy, or when AAD therapy is not tolerated, contraindicated or not desired; Implanted with an ICD (transvenous or subcutaneous) or CRT-D prior to the index ablation; for transvenous systems, leads must be implanted ≥30 days prior
  • Frequent premature ventricular complexes (PVCs) meeting class II a/b indications for ablation with documentation of PVCs on 24-Hour monitor in the 90 days prior to enrollment. Subjects should meet one or more of the following criteria:; Symptomatic PVCs when class I or III AADs have failed, are not tolerated, or are not desired (class II a); Suspected PVC-induced cardiomyopathy (>10% burden) (class II a); Frequent PVCs in patients with structural heart disease (>10% burden) (class II a); Asymptomatic, high burden PVCs (>15% burden) (class II b); Age 18 through 80 years old 3. Willing and able to provide written informed consent 4. Willing and able to comply with the study visit schedule and requirements

Ki nem vehet részt

  • Unstable angina within the prior 60 days
  • Myocardial infarction within 60 days prior to the ablation procedure
  • Any percutaneous coronary intervention within 60 days prior to the ablation procedure
  • Any cardiac surgery within 90 days prior to the ablation procedure
  • Currently receiving support or anticipated to receive support prior to the index ablation procedure, via extracorporeal membrane oxygenation (ECMO)
  • Thromboembolic event (stroke or transient ischemic attack) within 90 days prior to the index ablation procedure
  • Currently being evaluated for an organ transplant
  • Participation in another investigational study or treatment with any investigational drug within the previous 30 days that would interfere with this study. Each instance must be brought to the attention of the Sponsor to determine eligibility
  • Any of the following:; Any ablation procedure for VT or PVC within the previous 90 days of enrollment, or; More than 1 ablation procedure for VT or PVC within the previous 365 days of enrollment; SMMVT only exclusions:
  • Incessant VT necessitating hemodynamic support prior to the ablation procedure
  • Cardiac Conditions
  • Active myocardial ischemia
  • NYHA Class IV heart failure
  • Decompensated heart failure at the time of enrollment
  • The Micra™ Leadless Cardiac Implantable Electronic Device (CIED) or CIEDs with a left ventricular endocardial lead
  • Prohibitively distorted cardiac anatomy due to congenital heart disease; Vascular and Thromboembolic Conditions
  • Severe lung disease, pulmonary hypertension, or any lung disease involving abnormal blood gases or significant dyspnea
  • Active infection or sepsis
  • Serious or untreated medical conditions that would prevent participation in the study, interfere with assessment or therapy, or confound data or its interpretation
  • VTs due to any of the following:; Automaticity or triggered activity; Lamin or titin genetic mutation; VT secondary to electrolyte imbalance, active thyroid disease, or any other reversible or non-cardiac cause (e.g., drug-induced arrhythmia)
  • Left ventricular ejection fraction (LVEF) < 15%
  • Severe bleeding, clotting or thrombotic disorder, or thrombocytopenia (defined as platelet count < 80,000)
  • Chronic renal insufficiency of eGFR < 30 mL/min/1.73 m²; Systemic and General Medical Conditions
  • General Exclusion Criteria:
  • Ventricular assist device (VAD) implanted, planned, or required for the procedure
  • Severe aortic or mitral stenosis, or severe aortic or mitral regurgitation
  • Tricuspid or mitral valve replacement or repair (inclusive of Mitral/Tricuspid clips) or prosthetic valve procedure
  • Presence of intracardiac thrombus, tumor, or other abnormality that precludes vascular access, catheter introduction, or manipulation
  • Left atrium (LA) or left ventricle (LV) intracardiac thrombus on imaging
  • Contraindication to anticoagulation; Pulmonary and Renal
  • Life expectancy less than 12 months
  • Body mass index > 40 kg/m²
  • Pregnancy or breastfeeding; Study-Related Exclusions
  • Patient is not able to understand the nature of this study or is unwilling or unable to attend the study procedures
  • Non-ischemic cardiomyopathy (NICM)
  • Hypertrophic cardiomyopathy, except when due to an apical aneurysm
  • Unstable polymorphic VT or ventricular fibrillation (VF)
  • VT or VF thought to be from channelopathies

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 80 év között vagy?

Helyszínek itt: Horvátország

Még 3 másik országban, 4 helyszínen

  • University hospital of SplitSplit, HorvátországContact: Ante AnicRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study is a prospective, non-randomized, single-arm, multicenter study to evaluate the safety and effectiveness of the DuoVT Pulsed Field Ablation (PFA) System.

A vizsgálat csoportja

  • frequent premature ventricular complexes & sustained monomorphic ventricular tachycardia groupA vizsgált kezelés

    Ablation procedure of sustained monomorphic ventricular tachycardia (SMMVT) or frequent premature ventricular complexes (PVCs)

    Kezelés: Ablation procedure with DuoVT PFA system

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Illeszkedési kérdések
Forrás: NCT07706712: ki vehet részt
A regiszteradat frissítve
2026. október 16.